immatics is a biopharmaceutical company focused on the development of immunotherapeutic substances for cancer therapy. Founded by Hans Rammensee and Harpreet Singh in 2000, immatics biotechnologies is backed by investors that include Amgen, Celgene, KfW, Swisscom Ventures, and Wellington Partners and is headquartered in Tubingen.